Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Alignment Healthcare, Inc. (“Alignment” or “the Company”) (NASDAQ: ALHC). Investors who purchased Alignment securities are encouraged to obtain additional information and assist the investigation.

The investigation concerns whether Alignment has violated federal securities laws.

Alignment Investigation Details

On July 8, 2026, news emerged that a former Alignment Healthcare executive had filed a whistleblower complaint alleging that the Company engaged in “accounting irregularities” that “artificially inflated” Alignment’s previously reported and projected financial results, including “Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (‘Adjusted EBITDA’), a key non-GAAP financial metric central to the Company’s reported financial performance and executive compensation structure.” According to the lawsuit, “millions of dollars in operating expenses had been systematically misclassified as capital expenditures.” Following this news, Alignment’s stock price fell $4.02 per share, or 16.7%, to close at $20.03 per share on July 8, 2026.

What’s Next for Alignment Investors?

If you are aware of any facts relating to this investigation or purchased Alignment securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911